Ocular Therapeutix, Inc. (OCUL): Price and Financial Metrics
OCUL Price/Volume Stats
| Current price | $7.58 | 52-week high | $7.96 |
| Prev. close | $6.86 | 52-week low | $2.00 |
| Day low | $6.68 | Volume | 3,191,500 |
| Day high | $7.72 | Avg. volume | 1,473,876 |
| 50-day MA | $4.58 | Dividend yield | N/A |
| 200-day MA | $4.28 | Market Cap | 602.00M |
OCUL Stock Price Chart Interactive Chart >
OCUL POWR Grades
- Value is the dimension where OCUL ranks best; there it ranks ahead of 70.81% of US stocks.
- OCUL's strongest trending metric is Value; it's been moving up over the last 26 weeks.
- OCUL's current lowest rank is in the Stability metric (where it is better than 10.44% of US stocks).
OCUL Stock Summary
- OCULAR THERAPEUTIX INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 94.64% of US listed stocks.
- OCUL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 90.09% of US stocks.
- The volatility of OCULAR THERAPEUTIX INC's share price is greater than that of 87.07% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to OCULAR THERAPEUTIX INC are GH, CERS, FOLD, JAGX, and TVTX.
- OCUL's SEC filings can be seen here. And to visit OCULAR THERAPEUTIX INC's official web site, go to www.ocutx.com.
OCUL Valuation Summary
- In comparison to the median Healthcare stock, OCUL's price/sales ratio is 45.24% higher, now standing at 6.1.
- Over the past 115 months, OCUL's price/sales ratio has gone down 2175.4.
Below are key valuation metrics over time for OCUL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OCUL | 2023-12-29 | 6.1 | 45.1 | -5.3 | -5.6 |
| OCUL | 2023-12-28 | 6.2 | 45.7 | -5.4 | -5.7 |
| OCUL | 2023-12-27 | 6.2 | 45.5 | -5.3 | -5.7 |
| OCUL | 2023-12-26 | 6.0 | 44.4 | -5.2 | -5.5 |
| OCUL | 2023-12-22 | 5.7 | 41.9 | -4.9 | -5.2 |
| OCUL | 2023-12-21 | 5.7 | 41.8 | -4.9 | -5.1 |
OCUL Growth Metrics
- Its year over year net income to common stockholders growth rate is now at 83.04%.
- The 4 year revenue growth rate now stands at 233.19%.
- Its 2 year price growth rate is now at -45.39%.
The table below shows OCUL's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 49.726 | -57.798 | -59.346 |
| 2022-06-30 | 49.914 | -57.611 | -32.501 |
| 2022-03-31 | 49.366 | -66.791 | -22.216 |
| 2021-12-31 | 43.522 | -65.55 | -6.553 |
| 2021-09-30 | 38.562 | -56.643 | -88.315 |
| 2021-06-30 | 32.285 | -57.319 | -102.916 |
OCUL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- OCUL has a Quality Grade of C, ranking ahead of 60.31% of graded US stocks.
- OCUL's asset turnover comes in at 0.155 -- ranking 219th of 682 Pharmaceutical Products stocks.
- CASI, ONVO, and DRNA are the stocks whose asset turnover ratios are most correlated with OCUL.
The table below shows OCUL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.155 | 0.903 | -1.479 |
| 2021-03-31 | 0.125 | 0.903 | -1.953 |
| 2020-12-31 | 0.129 | 0.880 | -2.245 |
| 2020-09-30 | 0.138 | 0.818 | -1.315 |
| 2020-06-30 | 0.084 | 0.642 | -1.377 |
| 2020-03-31 | 0.077 | 0.525 | -1.196 |
OCUL Price Target
For more insight on analysts targets of OCUL, see our OCUL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $23.43 | Average Broker Recommendation | 1.43 (Moderate Buy) |
Ocular Therapeutix, Inc. (OCUL) Company Bio
Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts.
Latest OCUL News From Around the Web
Below are the latest news stories about OCULAR THERAPEUTIX INC that investors may wish to consider to help them evaluate OCUL as an investment opportunity.
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesBEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the closing of its previously announced underwritten public offering of 35,420,000 shares of its common stock at a public offering price of $3.25 per share, which includes 4,620,000 shares issued upon the exercise in full |
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 72% Price Boost Is Out Of Tune With RevenuesOcular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders would be excited to see that the share price has had a great... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning! |
Ocular Therapeutix™ Announces Pricing of Public Offering of Common StockBEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million, before deducting underwriting discounts and commi |
Ocular Therapeutix™ Announces Proposed Public Offering of Common StockBEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number o |
OCUL Price Returns
| 1-mo | 96.88% |
| 3-mo | 246.12% |
| 6-mo | 96.88% |
| 1-year | 20.89% |
| 3-year | -60.56% |
| 5-year | 103.76% |
| YTD | 69.96% |
| 2023 | 58.72% |
| 2022 | -59.68% |
| 2021 | -66.33% |
| 2020 | 424.05% |
| 2019 | -0.75% |
Continue Researching OCUL
Want to do more research on Ocular Therapeutix Inc's stock and its price? Try the links below:Ocular Therapeutix Inc (OCUL) Stock Price | Nasdaq
Ocular Therapeutix Inc (OCUL) Stock Quote, History and News - Yahoo Finance
Ocular Therapeutix Inc (OCUL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...